^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CIC deletion

    i
    Other names: CIC, Capicua Transcriptional Repressor, Protein Capicua Homolog, Capicua (Drosophila) Homolog, Capicua Homolog (Drosophila), KIAA0306, MRD45
    Entrez ID:
    23152
    Related biomarkers:
    Mutation
    7ms
    The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein. (PubMed, Cancer Res Commun)
    We also find that expression of C1-deleted CIC::DUX4 is capable of exerting intermediate transformation-related phenotypes compared with those imparted by full-length CIC::DUX4, but was not sufficient for tumorigenesis in a subcutaneous mouse model. In summary, our results suggest a supercharging role for the C1 domain in the activity of CIC::DUX4.
    Journal
    |
    DUX4 (Double Homeobox 4)
    |
    CIC deletion
    9ms
    RNA-based multiplex polymerase chain reaction and sequencing to detect fusion genes in melanoma (ESMO Asia 2024)
    Conclusions The Archer® FUSIONPlex® custom panel detected fusion genes in 10% of driver gene-negative melanomas. Combining DNA- and RNA-based multiplex sequencing is useful to identify potentially targetable gene alterations.
    Polymerase Chain Reaction • IO biomarker
    |
    NF1 (Neurofibromin 1) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • ETV1 (ETS Variant Transcription Factor 1) • MAD1L1 (Mitotic Arrest Deficient 1 Like 1) • MAP3K8 (Mitogen-Activated Protein Kinase Kinase Kinase 8) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • MEGF8 (Multiple EGF Like Domains 8) • RASGRF2 (Ras Protein Specific Guanine Nucleotide Releasing Factor 2)
    |
    BRAF mutation • KIT mutation • NF1 mutation • BRAF fusion • CIC deletion
    |
    Archer® FusionPlex® Sarcoma kit • FusionPlex® Dx
    over1year
    Loss of Capicua impairs oligodendrogenesis in the developing mouse brain (SNO 2023)
    We showed that OPC-specific Cic knockout results in increased cellular proliferation and maturation defects in the developing mouse brain. Cic loss may contribute to ODG formation by promoting developmental programs and inhibiting oligodendrocyte maturation in postnatal OPCs.
    Preclinical
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha)
    |
    CIC deletion
    2years
    Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    NF1 (Neurofibromin 1)
    |
    NF1 mutation • CIC deletion • CIC mutation
    |
    ulixertinib (BVD-523)
    over2years
    The CIC-ERF co-deletion underlies fusion-independent activation of ETS family member, ETV1, to drive prostate cancer progression. (PubMed, Elife)
    Targeting ETV1 in CIC and ERF-deficient prostate cancer limits tumor growth. Thus, we have uncovered a fusion-independent mode of ETS transcriptional activation defined by concurrent loss of CIC and ERF.
    Journal
    |
    ETV1 (ETS Variant Transcription Factor 1)
    |
    CIC deletion
    5years
    CIC is a critical regulator of neuronal differentiation. (PubMed, JCI Insight)
    Mass spectrometry analysis of CIC-interacting proteins further identified BRG1 containing mSWI/SNF complex whose function is necessary for transcriptional repression by CIC. Together, this study uncovers a novel regulatory pathway of CIC-dependent neuronal differentiation and may implicate these molecular mechanisms in CIC-dependent brain tumorigenesis.
    Journal
    |
    SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)
    |
    CIC deletion